Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 4,113 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Anxiety
Interventions: virtual reality relaxation headset; Device
Lead sponsor: Indiana University; Other
Eligibility: 13 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Meniscus Tear
Interventions: Meniscal Repair Procedure, BEAR Implant; Procedure · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Degenerative Disc Disease
Interventions: rhBMP-2/CRM/CD HORIZON® Spinal System, Autograft/CD HORIZON® Spinal System; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 28
States / cities: Phoenix, Arizona • Orange, California • Santa Monica, California + 25 more

Conditions: Primary Progressive Aphasia
Interventions: Communication Bridge™, Evidence-Based Impairment Focused; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 100 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Muscle Atrophy, Insulin Resistance
Interventions: Metformin (Bed Rest), Placebo (Bed Rest), Metformin (2 week run-in only), Placebo (2 week run-in only); Drug
Lead sponsor: University of Utah; Other
Eligibility: 60 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Oral Hygiene
Interventions: Experimental Dentifrice 1, Experimental Dentifrice 2, Reference Dentifrice; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Melbourne, Florida

Conditions: Smoking Behaviors, Cigarette Smoking
Interventions: Nicotine Messaging, Cigarette Condition; Other
Lead sponsor: Andrew Strasser; Other
Eligibility: 21 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: ONT01, Gemcitabine, Nab paclitaxel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prolonged Grief Disorder, Bereavement
Interventions: Syntocinon, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 55 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: SPY001-001, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Rheumatoid Arthritis
Interventions: SBT777101; Biological
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Francisco, California • Stanford, California + 4 more

Conditions: Opioid Use Disorder
Interventions: ERPs with electroencephalography (EEG), MIO; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obsessive-compulsive Disorder
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: Transcept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: Beverly Hills, California • Imperial, California • Los Angeles, California + 18 more

Conditions: Breast Cancer
Interventions: diffusion-weighted magnetic resonance imaging; Procedure
Lead sponsor: American College of Radiology Imaging Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Minneapolis, Minnesota + 4 more

Conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions: bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 79
States / cities: Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more

Conditions: Chronic Lower Limb Pain
Interventions: AXIUM Neurostimulator System, Control Spinal Cord Stimulation Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 22
States / cities: Phoenix, Arizona • Aptos, California • Carlsbad, California + 19 more

Conditions: Health Behavior
Interventions: LifePak Nano; Dietary Supplement
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, Ceftriaxone, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas + 1 more

Conditions: Infertility, Subfertility
Interventions: human chorionic gonadotropin (hCG), Placebo Comparator (for hCG); Drug
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Pancreatic Cancer
Interventions: mFOLFIRINOX, Ramucirumab, Placebo; Drug · Other
Lead sponsor: Walid Shaib, MD; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 8
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Indianapolis, Indiana + 5 more

Conditions: Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions: Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerset, New Jersey

Conditions: BK Polyomavirus, Kidney Diseases
Interventions: FK778; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 21
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 15 more

Conditions: Meningococcal Disease, Infections, Meningococcal
Interventions: MenACWY-CRM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 10 Years
Enrollment: 715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • Lake Mary, Florida + 15 more

Search by objective public record fields.

Effects of Virtual Reality Relaxation on the Anxiety Levels

Bridge-Enhanced ACL Repair (BEAR) in Meniscus Repair

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

Communication Bridge 2

Role of Metformin on Muscle Health of Older Adults

Clinical Study to Investigate the Tooth Stain Removal Efficacy of Two Experimental Toothpastes Compared to a Standard Toothpaste When Used Twice Daily for 8 Weeks

Impact of Nicotine Messaging on Beliefs and Behavior

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Oxytocin and Approach-avoid in Grief

A Study of SPY001-001 in Healthy Volunteers

Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis

Neuroplasticity in Maternal Opioid Use Disorder (OUD)

Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder

DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain

Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following a Dietary Supplement-based Intervention

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

A Study of Mirikizumab in Healthy Participants

Effect of hCG on Receptivity of the Human Endometrium

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.